Praful Ravi

15PUBLICATIONS

52CO-AUTHORS

Predictive and prognostic markersRadiation therapyMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (15)

Sort by Publication Date:

|May 23, 2026

Testosterone and docetaxel treatment effect on mortality risk in nonmetastatic high-risk prostate cancer: A predictive biomarker analysis.

|Apr 24, 2026

Efficacy and Safety of 177Lu-PSMA-617 in Elderly Patients With Metastatic Castration-Resistant Prostate Cancer.

|Jan 15, 2026

Current and future perspectives on radioligand therapy in advanced prostate cancer.

Buraq Ahmed, Praful Ravi

|Jan 12, 2026

Integrative Clinical and Molecular Evaluation of Renal Cell Carcinoma with Merlin Protein Deficiency and Biallelic Loss of NF2.

Emre Yekedüz, Weiwei Bian, Stephanie E Siegmund

|Mar 19, 2025

Outcome of Subsequent Therapies After <sup>177</sup>Lu-Vipivotide Tetraxetan for Metastatic Castrate-Resistant Prostate Cancer: A Tertiary Cancer Center Experience.

Meryam Losee, Michael Kavanaugh, Mofei Liu

|Jan 08, 2025

Evaluation of clinical risk stratification to determine benefit from long-term versus short-term androgen deprivation in high-risk localized prostate cancer.

Praful Ravi, Wanling Xie, Silke Gillessen

Pageof 3

Frequent Collaborators

Daniel S Childs

Heather Jacene

Atish D Choudhury

Anthony V D'Amico

Wanling Xie

Johnathan Zeng

Marco Bandini

Andrea Necchi

Matthew Mossanen

Adam S Kibel

Frequent Collaborators

Daniel S Childs

Heather Jacene

Atish D Choudhury

Anthony V D'Amico